...there is no subspecialty or business model that benefits from the attributes of a Management Company relationship more than Oncology...
Chicago, IL (PRWEB) November 17, 2016
Ziegler, a specialty investment bank, is pleased to announce it served as financial advisor to Oncology Hematology Care (OHC) in its recent partnership with The US Oncology Network (the Network), one of the nation’s largest associations of community-based oncology practices dedicated to advancing high-quality, evidence-based cancer care.
OHC has been the premier provider of advanced treatments for cancer and blood disorders in the Greater Cincinnati area for more than 30 years. With more than 50 expert oncology providers, OHC treats nearly every form of adult cancer and complex blood disorder with medical, radiation, gynecologic, palliative and hospice oncology specialists. OHC offers nationally recognized clinical trials to help achieve groundbreaking advancements in the treatment of cancer and leads the most experienced adult blood and marrow transplant center in the tri-state area.
The US Oncology Network is supported by McKesson Specialty Health, an industry leader in solutions that empower the community patient care delivery system to advance the science, technology and quality of care. This includes strong and comprehensive practice management capabilities and value-based care expertise critical for practices navigating today’s challenging healthcare landscape. OHC is one of more than 30 practices and over 1,000 physicians supported by McKesson Specialty Health nationally who have been selected to participate in the Center for Medicare & Medicaid Innovation Oncology Care Model, representing roughly 32 percent of all physicians selected to participate in the program. This is a testament to the commitment of both organizations to value-based, high-quality care.
Ziegler assisted in structuring and modeling the management services agreement, negotiating key terms of the partnership, presenting the partnership to OHC’s shareholders, and facilitating due diligence. By joining The US Oncology Network, OHC enhances its ability to provide patients high-quality care as well as access to some of the most advanced cancer treatments available today. The practice also gains a wealth of resources, expertise, innovative technologies and business support services from The Network to help them succeed in transitioning to value-based healthcare. OHC can utilize the industry-leading clinical pathways developed by The Network that provide evidence-based treatment options based on efficacy, toxicity and cost, reducing treatment variability while driving better outcomes and more predictable costs. Physicians will also be able to collaborate on difficult cases with their colleagues across America through eTumor Boards and The Oncology Portal, tapping into the collective knowledge and experience of more than 1,000 physicians. Additionally, the practice will have access to a state-of-the-art drug distribution center specifically developed to increase patient safety, as well as exciting new technologies and programs to support oncology practices as they transition to value-based care delivery models.
“Ziegler was a valued and trusted advisor in facilitating a fantastic outcome for the OHC shareholders. Ziegler provided crucial guidance on all aspects of the transaction including structuring and modeling the management services agreement, educating the OHC shareholders on the partnership, and delivering a successful close,” commented, Dr. E. Randolph Broun, President and Chairman of the Board of OHC.
Grant Chamberlain, Managing Director in Ziegler's Corporate Finance Healthcare practice, stated, “Having spent over 20 years advising physician practices in over 25 transactions in a wide variety of specialties (Anesthesiology, Oncology, Pathology, Radiology, and Primary Care), there is no subspecialty or business model that benefits from the attributes of a Management Company relationship more than Oncology. Oncology practices have a tremendous need to find skilled resources and capital to assist them in navigating the ever-increasing complexities of their business (i.e, evolving reimbursement models, IT infrastructure requirements, capital equipment acquisition needs, drug purchasing, research/clinical trials access, etc.) and US Oncology has perfected a win-win model for their affiliated practices to uniquely meet these requirements.”
Ziegler's Corporate Finance practice is focused on delivering best-in-class advisory and financing solutions for companies and organizations across the healthcare industry. In our core practice areas of healthcare services, information technology, hospitals and senior living, Ziegler is one of the most active M&A firms offering innovative sell-side, buy-side, recapitalization/restructuring, equity private placement and strategic partnering services.
For more information about Ziegler, please visit us at http://www.Ziegler.com.
The Ziegler Companies, Inc., together with its affiliates (Ziegler), is a privately held, specialty investment bank with unique expertise in complex credit structures and advisory services. Nationally, Ziegler is ranked as one of the leading investment banking firms in its specialty sectors of healthcare, senior living, religion, and education, as well as general municipal and structured finance. Headquartered in Chicago, IL with regional and branch offices throughout the U.S., Ziegler provides its clients with capital raising, corporate finance, FHA/HUD, strategic advisory services and research. Ziegler serves institutional and individual investors through its wealth management and capital markets distribution channels.
Certain comments in this news release represent forward-looking statements made pursuant to the provisions of the Private Securities Litigation Reform Act of 1995. This client’s experience may not be representative of the experience of other clients, nor is it indicative of future performance or success. The forward-looking statements are subject to a number of risks and uncertainties, in particular, the overall financial health of the securities industry, the strength of the healthcare sector of the U.S. economy and the municipal securities marketplace, the ability of the Company to underwrite and distribute securities, the market value of mutual fund portfolios and separate account portfolios advised by the Company, the volume of sales by its retail brokers, the outcome of pending litigation, and the ability to attract and retain qualified employees.
# # #